Phase 3: Evaluation and selection (week 5) Compare trial order results across candidates
Skipping applications or switching products too soon disrupts this cycle
Garca de Lucas MD, Caballero I, Fernndez-Garca JC, Domnguez-Rodrguez M, Moreno-Moreno P, Jimnez-Milln A, Botana-Lpez M, Avils B, Merino-Torres JF, Soto A
GLP-1R agonists, by regulating insulin release and lowering blood glucose levels, may help improve insulin resistance and glucose metabolism disorders, indirectly protecting the nervous system from damage
FDA guidance is direct on this point: don't use an injectable GLP-1 product that arrives warm or with inadequate refrigeration, since that can affect the medication's quality